Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations.
- DOI
- 10.1158/1535-7163.mct-26-0262
- Published
- 2026 Jul 30
- Container
- Molecular cancer therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-26-0262,
title = {Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations.},
author = {Sase H and Michisaka S and Tachibana Y and Hasegawa M and Fujii T and Takei K and Kanei T and Murao N and Komatsu R and Asanuma K and Kuramoto S and Shibahara N and Ohta A and Tanada M and Shiraishi T and Iikura H and Kitazawa T and Tanaka H},
year = {2026},
journal = {Molecular cancer therapeutics},
doi = {10.1158/1535-7163.mct-26-0262},
url = {https://doi.org/10.1158/1535-7163.mct-26-0262}
}RIS
TY - JOUR TI - Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations. AU - Sase H AU - Michisaka S AU - Tachibana Y AU - Hasegawa M AU - Fujii T AU - Takei K AU - Kanei T AU - Murao N AU - Komatsu R AU - Asanuma K AU - Kuramoto S AU - Shibahara N AU - Ohta A AU - Tanada M AU - Shiraishi T AU - Iikura H AU - Kitazawa T AU - Tanaka H PY - 2026 JO - Molecular cancer therapeutics DO - 10.1158/1535-7163.mct-26-0262 UR - https://doi.org/10.1158/1535-7163.mct-26-0262 ER -
APA
H, S., S, M., Y, T., M, H., T, F., K, T., T, K., N, M., R, K., K, A., S, K., N, S., A, O., M, T., T, S., H, I., T, K., & H, T. (2026). Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-26-0262
Source records
- pubmed · retrieved 2026-09-26T20:27:39.324Z